Expression of Class II Transplantation Antigen on Vascular Smooth Muscle Cells in Human Atherosclerosis

Lena Jonasson, Jan Holm, Omar Skalli, Giulio Gabbiani, and Göran K. Hansson
Arterial Biology Group, Departments of Histology and Medicine I, University of Göteborg, Sweden; Department of Surgery I, University of Göteborg, Sahlgrenska Hospital, Göteborg, Sweden; and Department of Pathology, University of Geneva, Switzerland

Abstract

A large proportion of the cells of the human atherosclerotic plaque is assumed to be derived from medial smooth muscle cells. In contrast to these, the cells of the plaque have the capacity to accumulate lipid, and they also proliferate at a higher rate than medial cells. It has therefore been suggested that smooth muscle cells undergo a change of phenotype during atherogenesis, but there has been no evidence for such a change on the molecular level. We have now analyzed carotid artery plaques using a battery of antibodies against cell surface and cytoskeletal antigens, and found that most of the cells express the class II transplantation antigen (II antigen) HLA-DR. Also, the beta chain of HLA-DR was detected by immunoblotting of plaque extracts with the OKIa1 monoclonal antibody. HLA-DR is normally present on cells of the immune system, but only 60% of the DR-positive cells of the plaque reacted with monoclonal antibodies specific for macrophages and lymphocytes. Many of the remaining DR-positive cells contained the muscle-specific intermediate filament protein, desmin. This indicates that smooth muscle cells of atherosclerotic plaques express DR antigen. In contrast, very few DR-positive cells were found in normal human arteries. This suggests that expression of class II antigen is part of a phenotypic change in smooth muscle cells in atherosclerosis.

Introduction

The major histocompatibility complex (MHC)1 encodes several groups of proteins. Among these, class I transplantation antigens (in humans, the HLA-ABC system) are expressed on almost all nucleated cells (1). In contrast, class II transplantation antigens (in humans, HLA-DR, HLA-DC, and HLA-SB, collectively often referred to as II antigens) are generally limited to cells involved in the immune system (2, 3). These glycoproteins, when present in the plasma membrane of macrophages, participate in the presentation of foreign antigens to T cells (2, 4). Other cells, such as endothelial cells and Langerhans' cells of the skin, may also express class II antigen (5-12), and they may also serve as antigen-presenting cells (5, 6, 11). Finally, class II antigens can be expressed on several other cell types under certain conditions. Intestinal, urinary, and other epithelia may express class II antigens, as well as several tumor cells (9, 13-21). The functional significance of this phenomenon is unknown, although it has been suggested that these cells might also present antigens to T cells (22).

In this study, we have detected class II antigen on smooth muscle cells in human atherosclerotic plaques with the use of antibodies to HLA-DR. The majority of the cells in surgical biopsies of carotid artery plaques expressed HLA-DR antigen. Only 60% of the cells were positive for markers for macrophages or leukocytes. Among the remaining DR-positive cells, many had desmin-containing intermediate filaments, and could therefore be identified as smooth muscle cells (23-25). In contrast, no smooth muscle cells were HLA-DR positive in biopsies of normal human arteries. These data suggest that smooth muscle cells, which do not normally express class II antigens, are induced to express HLA-DR in atherosclerosis.

Methods

Arterial tissue. Atherosclerotic arterial biopsies were obtained from 16 patients with atherosclerosis of the internal carotid arteries. The patients were between 48 and 70 yr old, and did not have any other systemic diseases. They were operated on due to cerebral manifestations, usually transitory ischemic attacks, and fibrofatty plaques were obtained during thrombendarterectomy. Nonatherosclerotic arterial biopsies were obtained from the aortic base during coronary bypass surgery, and from the uterine artery during hysterectomy. Coronary bypass patients (n = 5) were between 53 and 69 yr old, and hysterectomy patients (n = 4) were between 26 and 48 yr old. All biopsies were immersed in ice-cold Hank's balanced salt solution (HBSS), were transported to the laboratory, and processed further within 20 min after the excision. Carotid arteries were also obtained at the autopsies of four patients (aged 30, 64, 65, and 87 yr). The arteries were removed within 36 h after death, and were analyzed by immunofluorescence of frozen sections.

Antibodies: The mouse monoclonal antibody OKIa1, directed against human HLA-DR (26, 27), was obtained from Ortho Diagnostic Systems, Inc., Raritan, NJ, and the rat monoclonal YE2.36, also directed against the HLA-DR protein (28), was obtained from Seralab, Crawley Down, England. The mouse monoclonals anti-Leu-4, directed against a cell surface antigen on T lymphocytes (29), and anti-Leu-M3, directed against a surface antigen on monocytes and macrophages (30), were purchased from Becton-Dickinson & Co., Oxford, CA. DAKO-pan-B, a mouse monoclonal against a surface antigen on B lymphocytes, was bought from Dako, Copenhagen, Denmark. Rabbit antibodies to human Factor VIII and rhodamine-labeled swine-anti-rabbit IgG were bought from Dako, and biotinylated horse-anti-mouse IgG, goat-anti-rabbit IgG, and rabbit-anti-rat IgG were obtained from Vector Laboratories, Burlingame, CA.

Rabbit antibodies to vimentin were raised in the following way. Vimentin was isolated from cultured bovine endothelial cells by preparative electrophoresis (31), and rabbits were immunized three
times with Freund's incomplete adjuvant. A hyperimmune serum was obtained after a booster injection, and its specificity was tested by electroblotting and immunocytochemistry.

Antibodies to desmin were raised in rabbits immunized with chicken gizzard desmin (32). Specific antibodies were isolated from the antiserum by affinity chromatography as described (33).

Immunofluorescence. Parts of the specimens from all patients were embedded in OCT embedding medium (Miles Laboratories, Inc., Elkhart, IL) and snap-frozen in n-hexane that was chilled with liquid nitrogen. 8-μm sections were fixed for 5 min in 95% ethanol, rinsed in phosphate-buffered saline (PBS, 150 mM NaCl, 20 mM phosphate buffer, pH 7.2), and preincubated with 2% normal serum, immediately followed by incubations with either mouse or rat monoclonal antibodies or rabbit polyclonal antibodies, which were all diluted in PBS with 4% bovine serum albumin (Sigma Chemical Co., St. Louis, MO). After being rinsed repeatedly with PBS, the sections were incubated in a similar fashion with biotinylated antibodies against mouse, rat, and rabbit IgG, respectively. They were then rinsed again, incubated with fluorescein isothiocyanate (FITC)-labeled avidin (Vector Laboratories) at 25 μg/ml, rinsed, and mounted in PBS with 10% glycerol. The sections were examined in a fluorescence microscope (Ultraphot III; Carl Zeiss, Oberkochen, West Germany), equipped with an HBO50 lamp, epi-illumination, dielectric interference filters, and 20 × and 40 × fluorescence objectives. All antibodies were used at optimal dilutions determined by chessboard titrations. The following controls were performed: omission of (a) the first or (b) the second antibody, use of preimmune serum instead of (c) first or (d) second antibody, (e) use of an unrelated antibody instead of first antibody, or (f) use of an unrelated, biotinylated antibody instead of the second antibody.

A control for binding of the Fc part of specific antibodies to the Fc receptor of cells in the sections was made in the following way. Immune complexes were made by incubating human serum albumin with anti-albumin antibodies (Dako) at a molar ratio of 1:1, for 3 h at 37°C. After being washed, they were diluted in PBS (1:2, 1:20, and 1:200) and incubated on sections. The sections were then incubated with OK1a1, biotinylated anti-mouse IgG, and FITC-avidin.

The number of immunoreactive cells was determined in the following way. At a magnification of 200 (20 × objective), eight microscopic fields were randomly chosen in the plates. After counting, the sections were demounted and counterstained with Mayer's hemalum. Fields that had been counted were identified, and all nuclei were counted. Between 100 and 200 cells were present in each field.

In double-staining immunofluorescence experiments, sections were first incubated with a monoclonal antibody, followed by biotinylated anti-mouse IgG and FITC-avidin as described above. They were then exposed to rabbit-anti-Factor VIII, rabbit-anti-vimentin, or rabbit-anti-desmin antibodies followed by rhodamine-conjugated swine-anti-rabbit IgG. In controls, either one or both of the primary antibodies were omitted or substituted by preimmune IgG.

Histochemistry. Fresh cryostat sections were incubated for 40 min in a substrate solution for detection of alpha-naphthyl acetate esterase as described (34), and then counterstained with Mayer's hemalum.

Isolation of cells. Parts of the arterial biopsies were immediately cut into small pieces with fine forceps, washed twice in HBSS by low-speed centrifugation, and digested for 60 min at 37°C on a shaking water bath with a modification of the method described by Haley et al. (35). Digestion was with 900 IU/ml collagenase (Cl. histolyticum-collagenease type I, Sigma Chemical Co.), 1.0 mg/ml soybean trypsin inhibitor, 5.0 mg/ml bovine serum albumin in calcium- and magnesium-free HBSS. The digested material was filtered through a 150-μm mesh nylon filter, and cells were harvested by low-speed centrifugation. They were washed twice with HBSS, and subjected to the receptor assays described below. All glassware used with the cells were siliconized.

Fc receptor assay. This assay was performed essentially as described by Bianco et al. (36). In brief, a washed concentrated of sheep erythrocytes was incubated with anti-sheep erythrocyte antiserum (Statens Bakteriologiska Laboratorium, Stockholm, Sweden) for 60 min at room temperature. The coated erythrocytes were washed twice with PBS and suspended to a concentration of 1%. 500 μl of a suspension of the isolated arterial cells (10–20 × 10⁴ cells/ml), 200 μl fetal bovine serum (FBS, Flow Laboratories, Irvine, Scotland), and 10 drops of the erythrocyte suspension were mixed by centrifugation at 40 g for 5 min, and the loose pellet was incubated for 45 min at 37°C. The cells were resuspended, and drops of cells were air-dried onto microscopic slides and fixed with ice-cold acetone. Cells were counterstained with 0.1% Evans blue in PBS to quench erythrocyte autofluorescence, and then were stained with OK1a1 using the biotin-avidin immunofluorescent system as described above.

E receptor assay. T-cell specific E receptors (sheep erythrocyte receptors) were demonstrated as described (37). Briefly, AET-32-aminoethylisothiouronium-hydrobromide treated sheep erythrocytes were suspended to a concentration of 10%, and eight drops of this suspension were incubated for 5 min at 37°C with 500 μl of a suspension of isolated arterial cells and 200 μl FBS. The mixture was then centrifugated at 40 g for 5 min, and incubated as a loose pellet at 44°C overnight. The cells were resuspended, and HLA-DR-positive cells were detected with OK1a1 and biotin-avidin-immunofluorescence as described above.

Characterization of HLA-DR expression. Isolated plaque cells were divided into four portions. One was immediately fixed with acetone and stained for HLA-DR as described. The second portion was treated for 30 min at 37°C with 5 mM EDTA, 320 mM sucrose, 5 mM PBS, pH 7.4, to remove extrinsic plasma membrane proteins (38). After being washed in HBSS, the cells were analyzed for HLA-DR expression by immunofluorescence. The third portion of cells was incubated with 0.25% trypsin in PBS for 30 min at 37°C, washed with HBSS with 20% FBS, and analyzed for HLA-DR. The fourth portion was also treated with trypsin as described and washed with FBS-containing HBSS, but then incubated for 3 h at 37°C in HBSS-FBS before staining for HLA-DR. Some of the slides from the latter group were double-stained for HLA-DR and desmin as described above.

Electrophoresis and immunoblotting. 5-mm² pieces of human carotid artery atherosclerotic plaques were homogenized in SDS sample buffer (39) with a Polytron homogenizer, and the proteins were separated by SDS-polyacrylamide gel electrophoresis using a Laemmli system with a 10% separating gel. Part of the gel was stained with Coomassie Brilliant Blue; the rest was used for electroblotting. Polypeptides were transferred to nitrocellulose paper at 60 V in a Tris-glycine buffer, pH 8.3, with 20% methanol (40). One part of the paper was used for antibody incubations, and the other was stained with Amido black. For antibody staining, the paper was preincubated for 5 h with 0.3% gelatin in TBS (Tris-buffered saline, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4), followed by an 8-h incubation with OK1a1 at 1:100 in TBS-gelatin. After being rinsed, the paper was incubated for 6 h with 125I-labeled rabbit-anti-mouse IgG, rinsed again, and exposed to Kodak X-omat-AR film (Eastman Kodak Co., Rochester, NY) for 3 d at −85°C.

Results

Cell surface proteins were detected in human arterial tissue by immunofluorescence, using monoclonal antibodies to the cell surface protein, followed by biotinylated anti-mouse IgG and FITC-avidin. The class II transplantation antigen, HLA-DR, was detected with the monoclonal antibody OK1a1, which reacts with a framework determinant common to all allelic forms of the human HLA-DR protein (26). In the carotid plaques, many DR-positive cells were found immediately beneath the endothelium, but others were distributed throughout the fibrous cap and in the necrotic core of the plaque (Figs. 1 and 2). 69% of the cells in carotid atherosclerotic plaques contained HLA-DR antigen, and 37% of the cells in the nonatherosclerotic intima surrounding the plaque were HLA-DR positive (Table I). Similarly, 73% of the cells in aortic atherosclerotic plaques obtained at autopsy were DR-
positive. In contrast, intima from nonatherosclerotic carotid arteries contained only 7% DR-positive cells. Surgical biopsies of nonatherosclerotic aortas contained only 2% DR-positive cells, and biopsies of uterine arteries did not contain any DR-positive cells. (Fig. 3 A and B, Table I).

Standard immunofluorescent control experiments were all negative. In addition, the possibility of binding of antibodies to Fc receptors in the tissue was excluded by preincubation of sections with immune complexes. This did not affect the frequency of DR-positive cells (data not shown).

The HLA-DR antigen is known to be present on monocytes, macrophages, B lymphocytes, and certain T lymphocytes, and such cells were therefore identified in the vessel wall with monoclonal antibodies to cell type-specific antigens. In the carotid artery plaques, 29% of all cells were identified as monocyte/macrophages positive for the antibody Anti-Leu-M3 (Table I). Their distribution and number corresponded to that of alpha-naphyl acetate esterase-positive cells in parallel sections. The frequency of T cells, as defined by the pan-T cell antibody Anti-Leu-4, was 11%, and 1% of all cells were stained by the B cell-specific antibody Dako-pan-B. Monocytes, macrophages, B cells, and T cells could therefore account for only a fraction of the DR positive cells in the plaques. The data suggest that ~40% of the DR-positive cells of the plaque are not derived from the blood.

This conclusion was supported from studies of cells isolated from the plaques. As shown in Tables II and III, 60% of these cells were HLA-DR positive. 30% of the cells also expressed Fc-receptors, which are present on monocytes, macrophages, granulocytes, and some lymphocytes (41, 42), and only 5% had E rosettes characteristic of T cells (37).

**Figure 1.** Immunofluorescent detection of HLA-DR antigen at the edge of an atherosclerotic plaque from the carotid artery. A large proportion of the cells is HLA-DR positive. In addition, there is a yellow autofluorescence at the base of the plaque (lower right hand corner) (magnification of 500).

**Figure 2.** Immunofluorescent detection of HLA-DR antigen in the fibrous cap of an atherosclerotic plaque. Many DR-positive cells are seen (magnification of 1,000).
Table I. Immunoreactive Cells in Sections of Arterial Tissues*

<table>
<thead>
<tr>
<th>Tissue</th>
<th>OK1a1*</th>
<th>Leu-M3*</th>
<th>Leu-4*</th>
<th>pan-B*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carotid plaque (biopsy)</td>
<td>69±16</td>
<td>29±10</td>
<td>11±6</td>
<td>1±1</td>
</tr>
<tr>
<td>Intima surrounding</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>carotid plaque</td>
<td>37±12</td>
<td>8±4</td>
<td>4±3</td>
<td>0</td>
</tr>
<tr>
<td>(biopsy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carotid plaque</td>
<td>73</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>(autopsy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonatherosclerotic</td>
<td>7</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>carotid intima</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(autopsy)</td>
<td>2±2</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Aorta (biopsy)</td>
<td>0</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Uterine artery (biopsy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Values are given as percent of the total number of cells, mean±SD. NS, not studied.

Table II. Distribution of Fc Receptors and DR Reactivity among Cells Isolated From Plaques*

<table>
<thead>
<tr>
<th>DR reactivity</th>
<th>FcR*</th>
<th>FcR*</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>OK1a1*</td>
<td>24</td>
<td>36</td>
<td>60</td>
</tr>
<tr>
<td>OK1a1−</td>
<td>6</td>
<td>34</td>
<td>40</td>
</tr>
<tr>
<td>Total</td>
<td>30</td>
<td>70</td>
<td>100</td>
</tr>
</tbody>
</table>

* Values are given as percent of the total number of cells, means of two different experiments. FcR, Fc-receptor-positive cells by rosetting test.

To identify the nonleukocytic DR-positive cells, we used double-staining immunofluorescence. Biotin-avidin-FITC staining of HLA-DR was combined with staining of other proteins with polyclonal rabbit antibodies and rhodamine-labeled anti-rabbit IgG. In this way, endothelial cells were identified by rabbit-anti-Factor VIII, and none of these cells were DR-positive. Smooth muscle cells, the other major cell type of arteries, can be identified with antibodies to intermediate filament proteins. Most vascular smooth muscle cells contain vimentin-type intermediate filaments, but a fraction of the cells express desmin together with or instead of vimentin (43). Desmin-type filaments are specific for muscle cells and have not been observed in other cell types (23–25, 32, 33, 44, 45). Antibodies to desmin were therefore used as markers for smooth muscle cells. Double-staining experiments using rabbit-anti-desmin and OK1a1 revealed that 26±6% (mean±SD) of the DR-positive cells in the plaque contained desmin (Fig. 4). In contrast, there were no DR-positive, desmin-containing cells in the intima surrounding the plaque.

The cytoplasmic distribution of HLA-DR in the smooth muscle cells suggested that these cells synthesized the protein, but it could not be excluded that HLA-DR produced by other cells in the tissue might have adhered to the surface of muscle cells. A series of experiments was performed on isolated cells to answer this question (Fig. 5). First, isolated plaque cells were treated with EDTA under low ionic strength. This removes extrinsic proteins from the plasma membrane (38) but did not reduce the number of DR-positive cells. This number could, however, be reduced drastically by trypsin treatment (Fig. 5). When the cells were allowed to recover for 3 h after trypsinization, a large proportion of them regained DR-expression (Fig. 5). 3 h after trypsin treatment, 53.7% of the DR-positive cells were also desmin-positive in double-staining immunofluorescence. Taken together, these data show that the HLA-DR reactive antigen is actively expressed as an integral membrane protein of a large proportion of plaque cells, many of which are smooth muscle cells.

Table III. Distribution of E Receptors and DR Reactivity among Isolated Cells of the Plaque*

<table>
<thead>
<tr>
<th>DR reactivity</th>
<th>E*</th>
<th>E*</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>OK1a1*</td>
<td>2</td>
<td>58</td>
<td>60</td>
</tr>
<tr>
<td>OK1a1−</td>
<td>3</td>
<td>37</td>
<td>40</td>
</tr>
<tr>
<td>Total</td>
<td>5</td>
<td>95</td>
<td>100</td>
</tr>
</tbody>
</table>

* Values given as percent of total cells, means of two different experiments.

Figure 3. Immunofluorescent detection of HLA-DR antigen in non-atherosclerotic arterial tissue. (A) Base of aorta, removed during coronary bypass surgery. Two DR-positive cells are seen (magnification of 300). (B) Normal uterine artery, which does not contain any DR-positive cells, only a yellow autofluorescence of elastin (magnification of 600).
same cells, according to immunofluorescent experiments. OKIa1 and the rat monoclonal YE2.36 (28), which selectively binds to the alpha chain of HLA-DR in immunoblotting tests (Dr. Ian McConnell, University of Edinburgh, personal communication), stained the same number of cells in serial sections of the plaques (Table IV). Taken together, this indicates that the antigen in the plaque reacting with OKIa1 was HLA-DR, and not a cross-reacting protein.

**Discussion**

The characteristics of the cell type or cell types that form the atherosclerotic plaque has remained one of the most enigmatic in cardiovascular research. The vascular smooth muscle cell has the capacity to proliferate and form the fibrotic intimal thickening, which is an important part of the plaque (47). One would, however, have to postulate that it can change its phenotype significantly to explain many other characteristics of the plaque as a tissue, such as intracellular accumulation of cholesterol (48). It has therefore been suggested that the macrophage is a quantitatively important component of the plaque, alone or together with the smooth muscle cell (49, 50).

In this study, we show that smooth muscle cells can acquire one of the characteristic features of macrophages, namely the expression of class II transplantation antigen. Our data indicate that approximately two-thirds of the cells of the atherosclerotic plaque of the human carotid artery express HLA-DR antigen, and they suggest that many of these cells are smooth muscle cells. The dramatic increase in the frequency of DR-positive cells in atherosclerosis suggests that the expression of HLA-

**Table IV. Expression of the Alpha and Beta Chain of HLA-DR in Sections of Plaques**

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Positive cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>OKIa1</td>
<td>49.4±6.8</td>
</tr>
<tr>
<td>YE2.36</td>
<td>48.9±7.1</td>
</tr>
</tbody>
</table>

Number of cells stained by OKIa1 (directed against beta) and YE2.36 (anti-alpha) in corresponding regions of serial sections. Means (percent of total number of cells) ±SE, n = 12. Difference is not significant (Student's t test).

Figure 6. Identification of HLA-DR polypeptide in an atherosclerotic plaque by western blot. The left lane shows the polypeptide composition of the plaque by SDS-polyacrylamide electrophoresis and Coomassie Blue staining. To the right, the anti-HLA-DR antibody OKIa1 stains a band of ~28,000 Mr, corresponding to the beta chain of HLA-DR, on a nitrocellulose paper to which the polypeptides were transferred. Arrows to the left correspond to the position of relative molecular weight markers (94,000, 67,000, 43,000, 30,000, and 21,100 Mr, respectively).
DR on smooth muscle cells is linked to the development of the disease.

The detection of smooth muscle cells was based on the expression of the muscle-specific intermediate filament protein, desmin, in DR-positive cells. An alternative explanation to our results would therefore be that DR-positive cells such as macrophages might have started to produce desmin. This latter explanation is, however, very unlikely in view of the fact that while there are many examples in pathological conditions of DR expression by cells that are not normally involved in the immune system (e.g., 11, 14, 17, 19, 21), expression of desmin by nonmuscle cells has never been observed, even under pathological conditions or in cell culture (23–25, 32, 33).

Our conclusion is also supported by a comparison of the frequency of DR-positive cells with the frequencies of cells positive for other cell surface markers. Many of the cells of the monopoietic and lymphopoietic cell lineages are known to be DR-positive (2, 4). Quantitative evaluation of such cells with cell surface markers such as monoclonal antibodies and with receptor assays suggested that less than half of the cells in the plaques were derived from these lineages. In contrast, two-thirds of the cells of the plaques were DR-positive, implicating that many of the DR-positive cells were derived not from the blood but from the intrinsic cells of the vessel wall. The only marker for vascular cells that codistributed with HLA-DR was desmin, which points to a smooth muscle origin of these DR-positive cells. Almost one-third of the DR-positive cells of the plaque contained desmin. The remaining fraction of DR-positive cells was positive neither for desmin nor for the hematopoietic or lymphopoietic cell markers. Many cells in this category were probably also smooth muscle cells, since a large proportion of arterial smooth muscle cells contain vimentin but not desmin in their intermediate filaments (45).

As mentioned above, HLA-DR and related class II antigens (Ia antigens) in other species are expressed in immunocompetent cells such as monocytes, macrophages, B cells, and certain T cells (2, 4). They may, however, also be expressed in several epithelial cells (8, 9, 13–17, 19, 20, 22, 51) and endothelial cells (5, 6, 10–12). Cultured vascular endothelium starts to express HLA-DR when stimulated by lectins or immune interferon (10–12). This shows that the expression of class II antigens may be subjected to regulation. It is now important to identify the stimuli that induce HLA-DR expression on smooth muscle cells, and to determine which of these are active in the arterial intima during the development of atherosclerosis.

The only known function of class II antigens is to participate in the recognition of foreign antigens by T cells (2, 4). This reaction is followed by clonal proliferation of specific T cells (2). This proliferation is probably induced by two growth regulators; interleukin 1, which is produced by the macrophage, and the T cell product interleukin 2 (2). In analogy, "aberrant" expression of Ia antigens by other cells might be related to antigen presentation and/or growth stimulation. Data from studies of human umbilical vein endothelium suggest that these cells can substitute for macrophages as antigen-presenting cells (5). In recent studies of MRL mice, which develop an inherited autoimmune disease, Moyer and Reinisch (52) have shown that smooth muscle cells may express Ia antigen in vasculitis, and probably also present autoantigen(s) to T cells. One could speculate that this might also be the role of the HLA-DR positive smooth muscle cells of the atherosclerotic plaque. Alternatively, the expression of HLA-DR antigen might indicate that other macrophage-like features may be acquired by the smooth muscle cell, such as phagocytosis, receptor-mediated endocytosis of negatively charged proteins, and release of growth factors. A third possibility is that the expression of HLA-DR on these cells is without functional significance, and merely reflects a disturbance in the control of gene expression in smooth muscle cells of the atherosclerotic plaque.

Acknowledgments

We are indebted to Dr. Kerstin Boström and Dr. Sören Björkerud for giving us access to autopsy material and to Dr. Lars-Åke Nilsson for supplying reagents for rosetting assays.

This work was supported by grants from the Swedish Medical Research Council (projects 6816 and 4531), the Swedish National Association against Heart and Chest Diseases, the Swedish Society of Medical Sciences, Magnus Bergvall’s Foundation, the University of Göteborg, and the Swiss National Science Foundation (project 3.178-0.82).

References


Class II Transplantation Antigen in Atherosclerosis 131